DARA BioSciences, Inc. Receives Fast Track Designation From the U.S. FDA for KRN5500 for the Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer

RALEIGH, N.C., Aug. 18, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.